Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders

-Diagnostic investigations, including imaging and laboratory assays

-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases

-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies

-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.

Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

《血液肿瘤学》杂志刊登的文章涉及造血和淋巴系统肿瘤疾病的实验和临床方面以及相关事宜。特别欢迎将基础科学应用于临床问题的转化研究。鼓励投稿涉及以下领域的稿件：

-血液肿瘤的临床实践和管理，包括：急性和慢性白血病、恶性淋巴瘤、骨髓增生性疾病

-诊断研究，包括影像学和实验室检测

-血液疾病的血液肿瘤的流行病学、病理学和病理生物学

-治疗问题，包括 1、2 或 3 期试验以及同种异体和自体干细胞移植研究

-正常或患病造血和淋巴细胞的细胞生物学、分子生物学、分子遗传学和细胞遗传学方面，包括干细胞和细胞因子以及其他调节系统。

欢迎简明扼要、主题鲜明的综述材料，尤其是如果它能让更广泛的社区能够接触到新的概念和想法。可以与主编讨论评论材料的提案。只有具有更广泛的科学或临床相关性的病例材料和病例报告集合才会被考虑。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映血液学-医学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为3.3，平均审稿速度为 12周，或约稿 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。